| Original language | English |
|---|---|
| Pages (from-to) | 557-559 |
| Number of pages | 3 |
| Journal | European Journal of Heart Failure |
| Volume | 22 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2020 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction : the TOPCAT trial. / Ramalho, Sergio H.R.; Claggett, Brian L.; Sweitzer, Nancy K. et al.
In: European Journal of Heart Failure, Vol. 22, No. 3, 01.03.2020, p. 557-559.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction
T2 - the TOPCAT trial
AU - Ramalho, Sergio H.R.
AU - Claggett, Brian L.
AU - Sweitzer, Nancy K.
AU - Fang, James C.
AU - Shah, Sanjiv J.
AU - Anand, Inder S.
AU - Pitt, Bertram
AU - Lewis, Eldrin F.
AU - Pfeffer, Marc A.
AU - Solomon, Scott D.
AU - Shah, Amil M.
N1 - Funding Information: TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose. Funding Information: TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose. The authors wish to thank the staff and participants of the TOPCAT study for their important contributions. TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose.
PY - 2020/3/1
Y1 - 2020/3/1
UR - http://www.scopus.com/inward/record.url?scp=85074835452&partnerID=8YFLogxK
U2 - 10.1002/ejhf.1593
DO - 10.1002/ejhf.1593
M3 - Letter
C2 - 31667977
AN - SCOPUS:85074835452
SN - 1388-9842
VL - 22
SP - 557
EP - 559
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 3
ER -